NASDAQ · SLRN
Healthcare · Biotechnology
$2.27
Up+$0.00 (+0.00%)
Updated Sep 11, 2026, 5:01 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SLRN does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SLRN.
SLRN research
Company profile and research snapshot.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 7, 2025 | Citigroup | Neutral | — |
| Jan 7, 2025 | HC Wainwright & Co. | Neutral | — |
| Dec 11, 2024 | Wells Fargo | Overweight | — |
| Dec 11, 2024 | HC Wainwright & Co. | Neutral | — |
| Nov 14, 2024 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Benzinga · May 21, 2025
Alumis Inc. has completed its merger with ACELYRIN, Inc. The merger strengthens Alumis' balance sheet and supports the advancement of its late-stage pipeline of targeted therapies for immune-mediated diseases.
GlobeNewswire Inc. · May 13, 2025
Alumis Inc. and ACELYRIN, INC. announced that Alumis' stockholders voted to approve the pending merger between the two companies. The merger is expected to close in the second quarter of 2025, subject to customary closing conditions.
GlobeNewswire Inc. · May 13, 2025
ACELYRIN stockholders have approved the merger with Alumis, creating a new clinical biopharma company focused on developing transformative therapies for immune-mediated diseases.
Benzinga · May 1, 2025
ACELYRIN reiterates the benefits of its proposed merger with Alumis, stating that the combination will create a leading clinical-stage immunology company with a diversified portfolio and substantial runway to reach multiple value inflection points. The ACELYRIN board unanimously recommends that stockholders vote in favor of the merger.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLRN.
No results
No recent SID articles mention SLRN.
